Emergent BioSolutions Inks $174 Million COVID-19 Manufacturing Contract With AstraZeneca

Maryland-based Emergent BioSolutions has secured a $174 million contract with AstraZeneca for large-scale manufacturing of drug substances for the UK company’s COVID-19 vaccine.

Emergent will provide contract development and manufacturing services at its Baltimore Bayview facility for the commercial supply of the vaccine.

The new agreement expands upon an $87 million contract the companies signed in June.